- Home
- TOYO vs IKT Comparison
TOYO vs IKT Comparison
Compare TOYO & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOYO
- IKT
- Stock Information
- Founded
- TOYO 2022
- IKT 2008
- Country
- TOYO Japan
- IKT United States
- Employees
- TOYO N/A
- IKT N/A
- Industry
- TOYO
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- TOYO
- IKT Health Care
- Exchange
- TOYO NYSE
- IKT Nasdaq
- Market Cap
- TOYO 153.8M
- IKT 131.6M
- IPO Year
- TOYO N/A
- IKT 2020
- Fundamental
- Price
- TOYO $3.69
- IKT $1.89
- Analyst Decision
- TOYO
- IKT Buy
- Analyst Count
- TOYO 0
- IKT 2
- Target Price
- TOYO N/A
- IKT $8.00
- AVG Volume (30 Days)
- TOYO 12.5K
- IKT 521.7K
- Earning Date
- TOYO 08-21-2025
- IKT 08-13-2025
- Dividend Yield
- TOYO N/A
- IKT N/A
- EPS Growth
- TOYO 350.49
- IKT N/A
- EPS
- TOYO 1.09
- IKT N/A
- Revenue
- TOYO $176,957,128.00
- IKT N/A
- Revenue This Year
- TOYO N/A
- IKT N/A
- Revenue Next Year
- TOYO N/A
- IKT N/A
- P/E Ratio
- TOYO $3.40
- IKT N/A
- Revenue Growth
- TOYO 183.69
- IKT N/A
- 52 Week Low
- TOYO $1.36
- IKT $1.12
- 52 Week High
- TOYO $7.22
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- TOYO N/A
- IKT 51.83
- Support Level
- TOYO N/A
- IKT $1.56
- Resistance Level
- TOYO N/A
- IKT $2.04
- Average True Range (ATR)
- TOYO 0.00
- IKT 0.15
- MACD
- TOYO 0.00
- IKT 0.02
- Stochastic Oscillator
- TOYO 0.00
- IKT 69.47
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries, is engaged in research and development, production, and sales of solar cells. Geographically, the company generates revenue from Asia and the USA, out of which the majority of revenue is generated from Asia.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.